In the past 30 days, have you experienced a cough that has not fully gone away?
There is no vaccine for walking pneumonia. Antibiotics fail in nearly 40% of adult cases.
Walking pneumonia is caused by Mycoplasma pneumoniae, a bacterium with a 1 to 4 week silent incubation period. Most patients show no severe symptoms during this window — while the bacteria damages the airway lining.
Macrolide antibiotic resistance has risen from 4% in 2015 to nearly 40% today in severe adult presentations. The CDC is tracking resistance rates monthly.
No vaccine exists · CDC Surveillance 2026Have you experienced any of the following in the past 30 days?
Select all that apply
Which high-exposure environments are part of your weekly routine?
Select all that apply
How many times have you been ill with a respiratory symptom in the past 12 months?
Walking pneumonia bacteria enter the body through the nasal passages.
Mycoplasma pneumoniae uses specialized attachment proteins to grip the nasal epithelium — the mucosal tissue lining the interior of the nose. Within 72 hours, millions of bacteria anchor to the nasal lining and begin reproducing.
Once the bacteria attach, antibiotics cannot dislodge the colony. Current systemic treatments — oral antibiotics, immune supplements, flu vaccinations — do not provide direct protection at the nasal entry point.
A growing number of ICU physicians have adopted nasal antiseptic protocols to neutralize Mycoplasma pneumoniae before it can anchor and cause systemic infection.
Nasal passage = primary bacterial entry pointWhich preventive measures do you currently use?
Select all that apply
None of the measures listed above protect against walking pneumonia at the nasal entry point.
Vitamin supplements support the systemic immune response after infection has already occurred. Hand hygiene addresses fomite-based transmission. There is no flu vaccine that provides cross-protection against Mycoplasma pneumoniae.
Zero of the four most common preventive measures provide direct protection at the nasal epithelium — the primary site of walking pneumonia bacterial entry.
0 of 4 defenses address the nasal entry pointHow would you rate your concern about contracting a respiratory infection this year?
Do you have regular contact with immunocompromised individuals, elderly family, or young children?
Have you been prescribed any antibiotics in the past 2 years?
Prior antibiotic use is a primary risk factor for macrolide-resistant Mycoplasma pneumoniae.
Which age group applies to you?
Age is a primary variable in walking pneumonia risk stratification.
If a clinically validated, 10-second daily nasal hygiene protocol could reduce your exposure risk — would you adopt it?
Generating your risk assessment…
Assessment: Your nasal passages are currently unprotected against the circulating Mycoplasma pneumoniae strain.
Your responses indicate multiple compounding risk factors — including exposure frequency, reliance on preventive measures that do not address the nasal entry point, the absence of any available vaccine, and nearly 40% antibiotic failure rates in current adult cases.
Recommended: Nasal Antiseptic Protocol
A growing number of ER physicians and ICU nurses use povidone-iodine nasal spray — the same hospital-grade antiseptic used in surgical preparation — applied directly to the nasal passages. Clinical data indicates it neutralizes 99% of respiratory bacteria and viruses within 90 seconds at the point of entry. No known drug interactions. No rebound effect. 10 seconds, twice daily.